Inclusion Criteria:  Age from 18 to 75 years (including 18 and 75 years old); Newly-diagnosed glioblastoma confirmed by histopathological exams; IDH1- and IDH2-wild-type gliomas; Extent of resection of enhancing lesions > 90%; Karnofsky Performance Score(KPS) ≥ 60%; Adequate organ functions:  The absolute value of white blood cells ≥ 2.5×10 9/L; Hemoglobin levels> 100 g/L; Platelet counts > 100×109/L; Levels of Alanine aminotransferase, aspartate aminotransferase <2.5 x ULN; Serum creatinine levels <1.5 x ULN.  Exclusion Criteria:  Subjects with any other active malignancy; Subjects received the placement of Carmustine implants within 6 months before the inclusion; Subjects with active HBC, HCV or HIV infection; Subjects with grade 2 -3 hypertension or uncontrolled hypertension; Subjects with severe cardio- or cerebro- vascular diseases such as coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, cerebral thrombosis, cerebral hemorrhage, etc.; Subjects with uncontrolled autoimmune diseases such as hemolytic anemia, psoriasis and rheumatoid arthritis, etc.; Subjects with severe or uncontrolled psychiatric diseases or condition that could increase adverse events or interfere the evaluation of outcomes; Subjects receiving immunosuppressants after organ transplantation; Within four weeks before the DC vaccinations, subjects receiving systemic administration of steroids with dosage more than 10mg/d prednisone or the equivalent doses of other steroids ( not including inhaled corticosteroid); Subjects with unstable pulmonary embolism, deep venous embolism, or other major arterial and venous thromboembolic events that occur within 30 days before the enrollment; receiving ongoing anticoagulant therapy; Subjects in pregnancy or breastfeeding, or those who plan to become pregnant during treatment or within 2 months after the end of treatment; Within the 14 days before enrollment, subjects with active infections or uncontrolled infections that require systemic antibiotic treatment (except for simple urinary tract infections or upper respiratory tract infections); Subjects who have received other vaccine therapies or gene-modified cell therapy before enrollment; Subjects with number of the predicted neoantigen peptides less than 5; Subjects with other conditions that would interfere trial participation at the investigator's discretion; Subjects with medical conditions that affect signing the written informed consent or complying with the research procedures; or patients who are unwilling or unable to comply with the research procedures; Subjects who participated or are participating in other clinical trials within 4 weeks before enrollment.